TG Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present
at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9 – 10, 2021. The presentation will be accessible for on-demand download beginning on Tuesday, March 9, 2021 at
7:00 AM ET.
A replay of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and
autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from
the U.S. FDA for UKONIQ (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen
and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of
patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development. For more
information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.
Lesen Sie auch
UKONIQ is a trademark of TG Therapeutics, Inc.
CONTACT: | |
Investor Relations | |
Email: ir@tgtxinc.com | |
Telephone: 1.877.575.TGTX (8489), Option 4 | |
Media Relations: | |
Email: media@tgtxinc.com | |
Telephone: 1.877.575.TGTX (8489), Option 6 |